News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Amol Akhade: Can Perioperative Immunotherapy Change Outcomes in Resectable Gastric/GEJ Cancer?
Amol Akhade/hiranandanihospital.org
May 29, 2025, 17:41

Amol Akhade: Can Perioperative Immunotherapy Change Outcomes in Resectable Gastric/GEJ Cancer?

Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on LinkedIn:

“MATTERHORN Trial – ASCO 2025 Spotlight

Can perioperative immunotherapy change outcomes in resectable gastric/GEJ cancer?

At GI25, MATTERHORN (Durvalumab + FLOT) showed:

  • pCR: 19% vs 7%
  • T0: 23% vs 11%
  • N0: 52% vs 36%

As Per press release: EFS is statistically significant and clinically meaningful.

But KN585 – PCR BENIFIT but no EFS gain

Why MATTERHORN may succeed where KEYNOTE-585 fell short:

  • 100% got triplet chemo (vs 20% in KN585)
  • 60% completed peri-op FLOT (vs 48 % )

Now your turn- put your brain and give me your best guess for the EFS outcome?

HR and Gain in median EFS.

See the POLL and Vote on X.”

More posts featuring Amol Akhade.

Amol Akhade ASCO 2025 cancer Durvalumab gastric cancer GEJ cancer immunotherapy MATTERHORN OncoDaily Oncology
Special Coverage
Drugs
Jul 10, 2025, 01:19
Cisplatin in Cancer Treatment: Mechanism, Resistance, Toxicity, and Future Directions
Blog
Jul 9, 2025, 23:49
Sami Mansfield: Jumpstart July - Education plus Empowerment for Menopause After Cancer 
Insight
Jul 9, 2025, 23:06
Steven Rosenberg: The beginning of a new way to use immunotherapy
Blog
Jul 9, 2025, 22:10
Roland Busch: The busier the schedule, the more important the workout and discipline becomes
Blog
Jul 9, 2025, 21:45
Pierre Foidart: Honored to Receive Clinical Research Mandate from Stichting tegen Kanker - Fondation contre le Cancer
Blog
Jul 9, 2025, 21:20
Herbert Loong: Sarcomas Are a Group of Rare Diseases Which Benefits From Awareness and Specialist Care
Blog
Jul 9, 2025, 21:13
Asfand Yar Cheema: Calling All Internal Medicine Residents
Opinion
Jul 9, 2025, 21:08
Paolo Tarantino Opens the 3rd Annual ADC Toxicity Summit
Insight
Jul 9, 2025, 21:02
Marianna Vitaloni: I'm Incredibly Grateful to the Patients Who Shared Their Stories With Us
Blog
Jul 9, 2025, 20:28
Jennifer Guida: I Had the Privilege to Lead Pioneering Work at the NCI Focused on Cancer Survivorship, Healthy Aging, and Resilience
Blog
Jul 9, 2025, 20:27
Upcoming Global Cancer Research and Control Seminar Series - NCI Center for Global Health
Blog
Jul 9, 2025, 20:16
Rob Winn: Join for the Closing the Gap Cancer Summit